Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.
North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.

The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.

Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.

Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.

Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.

The global Human Coagulation Factor VIII market is valued at 7440 million US$ in 2018 and will reach 9420 million US$ by the end of 2025, growing at a CAGR of 3.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Human Coagulation Factor VIII market based on company, product type, end user and key regions.

This report studies the global market size of Human Coagulation Factor VIII in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Human Coagulation Factor VIII in these regions.
This research report categorizes the global Human Coagulation Factor VIII market by top players/brands, region, type and end user. This report also studies the global Human Coagulation Factor VIII market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS

Market size by Product
Recombinant Factor VIII
Plasma-derived Factor VIII
Market size by End User
Hemophilia A
Spontanous / Trauma
Surgical
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Human Coagulation Factor VIII market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Human Coagulation Factor VIII market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Human Coagulation Factor VIII companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Human Coagulation Factor VIII submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Human Coagulation Factor VIII are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Human Coagulation Factor VIII market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.